Cancer Vaccines
Study findings on cancer vaccines are outlined in reports from Army
Published in Vaccine Weekly, September 3rd, 2008
"The addition of Ii-Key, a four-amino-acid LRMK modification, increases vaccine potency when compared with unmodified class II epitopes. We present the results of the first human phase I trial of the Ii-Key hybrid HER-2/neu peptide (AE37) vaccine in disease-free, node-negative breast cancer patients. Patients and Methods The dose escalation trial included five dose groups, to determine safety and optimal dose of the hybrid peptide (100 mu g, 500 mu g, 1,000 mu g)...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2008-09-03)
More Articles from Vaccine Weekly
- Institute for Operations Research and the Management Sciences
New decision model seeks to avert flu vaccine mismatch of 2007-2008 season - Cytomegalovirus
Research from S. Gorman and co-researchers in the area of cytomegalovirus described - DNA Vaccines
Reports summarize DNA vaccines research from University of Sao Paulo - Foot and Mouth Disease
New foot and mouth disease research reported from S. Choudary and co-authors - Genital Herpesvirus
BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; a Vaccine Candidate for Genital Herpes - Immunization
Data from University of Massachusetts provide new insights into immunization - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
